1. Home
  2. MBAI vs TPST Comparison

MBAI vs TPST Comparison

Compare MBAI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.62

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

11.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
TPST
Founded
2004
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
11.3M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
MBAI
TPST
Price
$1.62
$2.27
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
161.0K
61.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.47
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.60
52 Week High
$3.92
$12.22

Technical Indicators

Market Signals
Indicator
MBAI
TPST
Relative Strength Index (RSI) 47.23 36.43
Support Level $1.31 $2.16
Resistance Level $1.87 $3.18
Average True Range (ATR) 0.16 0.13
MACD -0.02 0.02
Stochastic Oscillator 33.49 30.38

Price Performance

Historical Comparison
MBAI
TPST

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: